Substituted dihydropyrazolones for treating cardiovascular and hematological diseases

Abstract

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

1 . A compound of the formula (I) 
       
         
           
           
               
               
           
         
         in which 
         R 1  represents a heteroaryl group of the formula 
       
       
         
           
           
               
               
           
         
         
           wherein 
           * denotes the linkage point with the dihydropyrazolone ring, 
           A in each individual occurrence denotes C—R 4  or N, wherein at most two ring members A represent N at the same time, 
           and 
           E denotes O, S or N—R 5    
         
         R 2  represents a heteroaryl group of the formula 
       
       
         
           
           
               
               
           
         
         
           wherein 
           # denotes the linkage point with the dihydropyrazolone ring, 
           G in each individual occurrence denotes C—R 6  or N, wherein at most two ring members G represent N at the same time, 
           J denotes O, S or N—R 7    
           and 
           L in each individual occurrence denotes C—R 8  or N, wherein at most two ring members L represent N at the same time,
 wherein 
 R 4 , R 6  and R 8  are identical or different and in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of halogen, cyano, nitro, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, —C(═O)—R 9 , —C(═O)—OR 10 , —C(═O)—NR 11 R 12 , —O—C(═O)—R 13 , —O—C(═O)—NR 14 R 15 , —NR 16 —C(═O)—R 17 , —NR 18 —C(═O)—OR 19 , —NR 20 —C(═O)—NR 21 R 22 , —NR 23 —SO 2 —R 24 , —SO 2 —R 25 , —SO 2 —NR 26 R 27 , —OR 28 , —SR 29  and —NR 30 R 31 , wherein
 (i) (C 1 -C 6 )-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of halogen, cyano, oxo, (C 3 -C 7 )-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, —C(═O)—R 9 , —C(═O)—OR 10 , —C(═O)—NR 11 R 12 , —O—C(═O)—R 13 , —O—C(═O)—NR 14 R 15 , —NR 16 —C(═O)—R 17 , —NR 18 —C(═O)—OR 19 , —NR 20 —C(═O)—NR 21 R 22 , —NR 23 —SO 2 —R 24 , —SO 2 —R 25 , —SO 2 —NR 26 R 27 , —OR 28 , —SR 29  and —NR 30 R 31 , 
  wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 (ii) (C 3 -C 7 )-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of (C 1 -C 6 )-alkyl, halogen, cyano, oxo, —C(═O)—R 9 , —C(═O)—OR 10 , —C(═O)—NR 11 R 12 , —O—C(═O)—R 13 , —O—C(═O)—NR 14 R 15 , —NR 16 —C(═O)—R 17 , —NR 18 —C(═O)—OR 19 , —NR 20 —C(═O)—NR 21 R 22 , —NR 23 —SO 2 —R 24 , —SO 2 —R 25 , —SO 2 —NR 26 R 27 , —OR 28 , —SR 29  and —NR 30 R 31 , 
  wherein the alkyl radical mentioned last can in its turn be substituted up to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl, (C 3 -C 7 )-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl, 
 (iii) R 9 , R 10 , R 11 , R 13 , R 14 , R 17 , R 19 , R 21 , R 24 , R 25 , R 26 , R 28 , R 29  and R 30  independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein 
  (C 3 -C 7 )-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl 
  and 
  (C 1 -C 6 )-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl, (C 3 -C 7 )-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl, 
 (iv) R 12 , R 15 , R 16 , R 18 , R 20 , R 22 , R 23 , R 27  and R 31  independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C 1 -C 6 )-alkyl, 
  wherein (C 1 -C 6 )-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 and/or wherein 
 (v) R 11  and R 12 , R 14  and R 15 , R 16  and R 17 , R 18  and R 19 , R 20  and R 21 , R 21  and R 22 , R 23  and R 24 , R 26  and R 27  and R 30  and R 31  in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once to three times in an identical or different manner by halogen, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 
 and 
 R 5  and R 7  are identical or different and independently of one another represent hydrogen or a substituent chosen from the series consisting of (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein
 (i) (C 1 -C 6 )-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of halogen, cyano, oxo, (C 3 -C 7 )-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, —C(═O)—R 9 , —C(═O)—OR 10 ,—C(═O)—NR 11 R 12 , —O—C(═O)—R 13 , —O—C(═O)—NR 14 R 15 , —NR 6 —C(═O)—R 17 —NR 18 —C(═O)—OR 19 , —NR 20 —C(═O)—NR 21 R 22 , —NR 23 —SO 2 —R 24 , —SO 2 —R 25 , —SO 2 —NR 26 R 27 , —OR 28 , —SR 29  and —NR 30 R 31 , 
  wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 and 
 (ii) (C 3 -C 7 )-cycloalkyl, 4-to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of (C 1 -C 6 )-alkyl, halogen, cyano, oxo, —C(═O)—R 9 , —C(═O)—OR 10 , —C(═O)—NR 11 R 12 , —O—C(═O)—R 13 , —O—C(═O)—NR 14 R 15 , —NR 16 —C(═O)—R 17 , —NR 18 —C(═O)—OR 19 , —NR 20 —C(═O)—NR 21 R 22 , —NR 23 —SO 2 —R 24 , —SO 2 —R 25 , —SO 2 —NR 26 R 27 , —OR 28 , —SR 29  and —NR 30 R 31 , 
  wherein the alkyl radical mentioned last in its turn can be substituted up to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl, (C 3 -C 7 )-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl, 
 wherein 
 (a) R 9 , R 10 , R 11 , R 13 , R 14 , R 17 , R 19 , R 21 , R 24 , R 25 , R 26 , R 28 , R 29  and R 30  independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein 
  (C 3 -C 7 )-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl 
  and 
  (C 1 -C 6 )-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl, (C 3 -C 7 )-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl, 
 (b) R 12 , R 15 , R 16 , R 18 , R 20 , R 22 , R 23 , R 27  and R 31  independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C 1 -C 6 )-alkyl, 
  wherein (C 1 -C 6 )-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 and/or 
 (c) R 11  and R 12 , R 14  and R 15 , R 16  and R 17 , R 18  and R 19 , R 20  and R 21 , R 21  and R 22 , R 23  and R 24 , R 26  and R 27  and R 30  and R 31  in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once to three times in an identical or different manner by halogen, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 
 
         
         and 
         R 3  represents hydrogen, (C 1 -C 6 )-alkyl or (C 3 -C 7 )-cycloalkyl, 
         and their salts, solvates and solvates of the salts, 
         with the exception of the compounds 
         3-methyl-1-(pyridin-2-yl)-4-(1-pyridin-2-yl-3-methyl-1H-pyrazol-5-yl)-2H-3-pyrazolin-5(1H)-one, 
         3′,5-dimethyl-2-phenyl-1′-(4-phenyl-1,3-thiazol-2-yl)-1′H,2H-3,4′-bipyrazol-5′-ol, 
         3′,5-dimethyl-2-phenyl-1′-(4-thiophen-2-yl-1,3-thiazol-2-yl)-1′H,2H-3,4′-bipyrazol-5′-ol, 
         3′,5-dimethyl-1′-(4-methyl-,3-thiazol-2-yl)-2-phenyl-1′H,2H-3,4′-bipyrazol-5′-ol, 
         2-(4-chlorophenyl)-3′,5-dimethyl-1′-(4-phenyl-1,3-thiazol-2-yl)-1′H,2H-3,4′-bipyrazol-5′-ol 
         and 
         2-tert-butyl-1′-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3′,5-dimethyl-1′H,2H-3,4′-bipyrazol-5′-ol. 
       
     
     
         2 . A compound of the formula (I) as claimed in  claim 1 , in which
 R 1  represents a heteroaryl group of the formula   
       
         
           
           
               
               
           
         
         
           wherein 
           * denotes the linkage point with the dihydropyrazolone ring, 
           A in each individual occurrence denotes C—R 4  or N, wherein at most two ring members A represent N at the same time, wherein
 R 4  in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, nitro, (C 1 -C 6 )-alkyl, hydroxyl, (C 1 -C 6 )-alkoxy, trifluoromethoxy, amino, mono-(C 1 -C 6 )-alkylamine, di-(C 1 -C 6 )-alkylamino, hydroxycarbonyl and (C 1 -C 6 )-alkoxycarbonyl,
 wherein the (C 1 -C 6 )-alkyl radical mentioned in its turn can be substituted up to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 
 
           and 
           E denotes O, S or N—R 5 , wherein
 R 5  represents hydrogen or (C 1 -C 6 )-alkyl, 
 
         
         R 2  represents a heteroaryl group of the formula 
       
       
         
           
           
               
               
           
         
         
           wherein 
           # denotes the linkage point with the dihydropyrazolone ring, 
           G in each case denotes C—R 6  or N, wherein not more than one of the two ring members G represents N, wherein
 R 6  in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, —C(═O)—OR 10 , —C(═O)—NR 11 R 12 , —O—C(═O)—R 13 , —O—C(═O)—NR 14 R 15 , —NR 16 —C(═O)—R 17 , —NR 18 —C(═O)—OR 19 , —NR 20 —C(═O)—NR 21 R 22 , —NR 23 —SO 2 —R 24 , —OR 28  and —NR 30 R 31 , wherein
 (i) (C 1 -C 6 )-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, —C(═O)—OR 10 , —C(═O)—NR 11 R 12 , —O—C(═O)—R 13 , —O—C(═O)—NR 14 R 15 , —NR 16 —C(═O)—R 17 , —NR 18 —C(═O)—OR 19 , —NR 20 —C(═O)—NR 21 R 22 , —NR 23 —SO 2 —R 24 , —OR 28  and —NR 30 R 31 , 
  wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 (ii) (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 (iii) R 10 , R 11 , R 13 , R 14 , R 17 , R 19 , R 21 , R 24 , R 28  and R 30  independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein 
  (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
  and 
 (C 1 -C 6 )-alkyl can be substituted once to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl, (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl, 
 
 (iv) R 12 , R 15 , R 16 , R 18 , R 20 , R 22 , R 23  and R 31  independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C 1 -C 6 )-alkyl,
 wherein (C 1 -C 6 )-alkyl can be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 
 and/or wherein
 (v) R 11  and R 12 , R 14  and R 15 , R 16  and R 17 , R 18  and R 19 , R 20  and R 21 , R 21  and R 22 , R 23  and R 24  and R 30  and R 31  in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 —C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 
 
           and 
           J denotes O or S, 
         
         and 
         R 3  represents hydrogen or methyl, 
         and their salts, solvates and solvates of the salts. 
       
     
     
         3 . A compound of the formula (I) as claimed in  claim 1 , in which
 R 1  represents a heteroaryl group of the formula   
       
         
           
           
               
               
           
         
         
           wherein 
           * denotes the linkage point with the dihydropyrazolone ring, 
           A in each individual occurrence denotes C—R 4  or N, wherein at most one of the ring members A represents N, wherein
 R 4  in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, nitro, (C 1 -C 6 )-alkyl, hydroxyl, (C 1 -C 6 )-alkoxy, trifluoromethoxy, amino, mono-(C 1 -C 6 )-alkylamine, di-(C 1 -C 6 )-alkylamino, hydroxycarbonyl and (C 1 -C 6 )-alkoxycarbonyl,
 wherein the (C 1 -C 6 )-alkyl radical mentioned in its turn can be substituted up to three times in an identical or different manner by fluorine, hydroxyl, trifluoromethoxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 
 
           and 
           E denotes O or S, 
         
         R 2  represents a heteroaryl group of the formula 
       
       
         
           
           
               
               
           
         
         
           wherein 
           # denotes the linkage point with the dihydropyrazolone ring, 
           G in each case denotes C—R 6  or N, wherein not more than one of the two ring members G represents N, wherein
 R 6  in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, —C(═O)—OR 10 , —C(═O)—NR 11 R 12 , —NR 16 —C(═O)—R 17 , —NR 18 —C(═O)—ONR 19 , —OR 28  and —NR 30 R 31 , wherein
 (i) (C 1 -C 6 )-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of fluorine, (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, —C(═O)—OR 10 , —C(═O)—NR 11 R 12 , —NR 16 —C(═O)—R 17 , —NR 18 —C(═O)—OR 19 , —OR 28  and —NR 30 R 31 , 
  wherein the cycloalkyl, heterocycloalkyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 (ii) (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C 1 -C 6 )-alkyl, hydroxyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
  wherein (C 1 -C 6 )-alkyl in its turn can be substituted up to three times in an identical or different manner by fluorine, hydroxyl, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl, (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl, 
 (iii) R 10 , R 11 , R 17 , R 19 , R 28  and R 30  independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl and 4-to 6-membered heterocycloalkyl, wherein 
  (C 3 -C 6 )-cycloalkyl and 4- to 6-membered heterocycloalkyl in their turn can in each case be substituted up to three times in an identical or different manner by fluorine, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl 
  and 
  (C 1 -C 6 )-alkyl can be substituted once to three times in an identical or different manner by fluorine, hydroxyl, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl, (C 3 -C 6 )-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl, 
 (iv) R 12 , R 16 , R 18  and R 31  independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C 1 -C 6 )-alkyl, 
  wherein (C 1 -C 6 )-alkyl can be substituted once or twice in an identical or different manner by fluorine, hydroxyl, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 and/or wherein 
 (v) R 11  and R 12 , R 16  and R 17 , R 18  and R 19  and R 30  and R 31  in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once or twice in an identical or different manner by fluorine, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 
 
           and 
           J denotes O or S, 
         
         and 
         R 3  represents hydrogen, 
         and their salts, solvates and solvates of the salts. 
       
     
     
         4 . A compound of the formula (I) as claimed in  claim 1 , in which
 R 1  represents a heteroaryl group of the formula   
       
         
           
           
               
               
           
         
         
           wherein 
           * denotes the linkage point with the dihydropyrazolone ring 
           and 
           R 4  denotes hydrogen, fluorine, chlorine, bromine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxymethyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, hydroxycarbonyl or (C 1 -C 4 )-alkoxycarbonyl, 
         
         R 2  represents a heteroaryl group of the formula 
       
       
         
           
           
               
               
           
         
         
           wherein 
           # denotes the linkage point with the dihydropyrazolone ring 
           and 
           R 6 , R 6A  and R 6B  are identical or different and independently of one another denote hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C 1 -C 6 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 6 )-alkoxy, trifluoromethoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl and 4- to 6-membered heterocycloalkyl, wherein
 (C 1 -C 6 )-alkyl in its turn can be substituted by hydroxyl, (C 1 -C 4 )-alkoxy or amino 
 and 
 4- to 6-membered heterocycloalkyl in its turn can be substituted once or twice in an identical or different manner by fluorine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl, 
 
         
         and 
         R 3  represents hydrogen, 
         and their salts, solvates and solvates of the salts. 
       
     
     
         5 . 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1H-imidazol-1-yl]-1,2-dihydro-3H-pyrazol-3-one according to  claim 1  having the following formula 
       
         
           
           
               
               
           
         
         and its salts, solvates and solvates of the salts. 
       
     
     
         6 . 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1H-imidazol-1-yl]-1,2-dihydro-3H-pyrazol-3-one according to  claim 1  having the following formula 
       
         
           
           
               
               
           
         
       
     
     
         7 . 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1H-imidazol-1-yl]-1,2-dihydro-3H-pyrazol-3-one hydrochloride according to  claim 1  having the following formula 
       
         
           
           
               
               
           
         
       
     
     
         6 . A process for the preparation of a compound of the formula (I) as defined in  claim 1 , characterized in that a compound of the formula (II) 
       
         
           
           
               
               
           
         
         in which R 1  and R 3  in each case have the meanings given in  claim 1  and 
         Z 1  represents methyl or ethyl, 
         is reacted in an inert solvent, optionally in the presence of an acid, with a compound of the formula (III) 
       
       
         
           
           
               
               
           
         
         in which R 2  has the meaning given in  claim 1 , 
         to give compounds of the formula (IV) 
       
       
         
           
           
               
               
           
         
         in which Z 1 , R 1 , R 2  and R 3  have the meaning given in  claim 1 , 
         which cyclize already under these reaction conditions or in a subsequent reaction step under the influence of a base to give the compounds of the formula (I), 
         and the compounds of the formula (I) are optionally converted with the corresponding (i) solvents and/or (ii) bases or acids into their solvates, salts and/or solvates of the salts. 
       
     
     
         7 . A process for the preparation of a compound of the formula (I) as defined in  claim 1  in which R 3  denotes hydrogen, characterized in that a compound of the formula (V) 
       
         
           
           
               
               
           
         
         in which R 1  has the meaning given in  claim 1  and 
         Z 1  represents methyl or ethyl, 
         is subjected to a condensation reaction with a compound of the formula (VI) 
       
       
         
           
           
               
               
           
         
         in which 
         Z 2  represents methyl or ethyl, 
         to give compounds of the formula (VII) 
       
       
         
           
           
               
               
           
         
         in which Z 1  and R 1  have the meaning given in  claim 1 , 
         and these are subsequently reacted in the presence of an acid with a compound of the formula (III) 
       
       
         
           
           
               
               
           
         
         in which R 2  has the meaning given in  claims 1 , 
         to give compounds of the formula (IV-A) 
       
       
         
           
           
               
               
           
         
         in which Z 1 , R 1  and R 2  have the meaning given in  claim 1 , 
         which cyclize already under these reaction conditions or in a subsequent reaction step under the influence of a base to give the compounds of the formula (I) wherein R 3  represents hydrogen. 
       
     
     
         8 . A pharmaceutical composition comprising a compound according to  claim 1  and an inert, non-toxic, pharmaceutically suitable auxiliary substance. 
     
     
         9 . A pharmaceutical composition comprising the compound according to  claim 5  and an inert, non-toxic, pharmaceutically suitable auxiliary substance. 
     
     
         10 . A pharmaceutical composition comprising the compound according to  claim 6  and an inert, non-toxic, pharmaceutically suitable auxiliary substance. 
     
     
         11 . A pharmaceutical composition comprising a compound according to  claim 7  and an inert, non-toxic, pharmaceutically suitable auxiliary substance. 
     
     
         12 . A pharmaceutical composition comprising a compound according to  claim 1  and one or more additional active compounds chosen from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, beta receptor blockers, calcium antagonists, PDE inhibitors, mineralocorticoid receptor antagonists, diuretics, aspirin, iron supplements, vitamin B12 and folic acid supplements, statins, digitalis (digoxin) derivatives, tumor chemotherapeutics and antibiotics. 
     
     
         13 . A method for the treatment and/or prophylaxis of cardiovascular disease, cardiac insufficiency, anemia, chronic kidney disease or renal insufficiency comprising administering to a human or animal in need thereof an active amount of at least one compound according to  claim 1 . 
     
     
         14 . A method for the treatment and/or prophylaxis of cardiovascular disease, cardiac insufficiency, anemia, chronic kidney disease or renal insufficiency comprising administering to a human or animal in need thereof an active amount of the compound according to  claim 5 . 
     
     
         15 . A method for the treatment and/or prophylaxis of cardiovascular disease, cardiac insufficiency, anemia, chronic kidney disease or renal insufficiency comprising administering to a human or animal in need thereof an active amount of the compound according to  claim 6 . 
     
     
         16 . A method for the treatment and/or prophylaxis of cardiovascular disease, cardiac insufficiency, anemia, chronic kidney disease or renal insufficiency comprising administering to a human or animal in need thereof an active amount of the compound according to  claim 7 . 
     
     
         17 . A method for the treatment and/or prophylaxis of cardiovascular disease, cardiac insufficiency, anemia, chronic kidney disease or renal insufficiency comprising administering to a human or animal in need thereof an active amount of at least one pharmaceutical composition according to  claim 8 .